Caribou Biosciences welcomes Andrew Guggenhime to its Board of Directors

– USA, CA –  Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Andrew Guggenhime to its board of directors.

Mr. Guggenhime is an accomplished biopharmaceutical industry leader with more than 20 years of experience.

“Andrew brings a wealth of financial, strategic, and operational leadership experience in both private and public healthcare company settings,” said CEO, Dr. Rachel Haurwitz. “We are delighted to welcome him to our board of directors and look forward to benefitting from his expertise as we continue to build the company and advance our pipeline of chRDNA-edited allogeneic cell therapies.”

About Andrew Guggenhime

Mr. Guggenhime currently serves as president and CFO of Vaxcyte, Inc., which he joined in 2020. He helped lead Vaxcyte’s initial public offering and established the infrastructure to enable public company compliance. Before joining Vaxcyte, Mr. Guggenhime served as CFO for several biotech companies including Dermira, Inc., Calistoga Pharmaceuticals, Inc., and Facet Biotech Corporation. Mr. Guggenhime has executed a wide range of financial and strategic transactions, helped scale organizations from research to clinical to the commercial stage, and built and led business planning and process initiatives for multiple corporate functions. He began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. Mr. Guggenhime is also a member of the board of directors of Metacrine, Inc.

“Caribou is an exciting company, using its technology to expand the promise of cell therapies for cancer treatment,” said Mr. Guggenhime. “I look forward to working closely with the Caribou leadership team and the other directors as the company begins its phase 1 study for the first of its differentiated allogeneic cell therapies and continues to develop its proprietary chRDNA platform.”

He earned his B.A. in International Politics and Economics from Middlebury College and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University.

About Caribou Biosciences, Inc.

Caribou is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company’s proprietary chRDNA technology toward the development of next-generation, genome-edited cell therapies with best-in-class potential. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors for clinically validated targets as well as new targets.

For more information: https://www.cariboubio.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.